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Abstract
Background: The stability of ophthalmic preparations in multidose containers is influenced by the
preservative as well as the stability of the active ingredient. Unstable drugs may require
refrigeration to preserve their active ingredient level and they are more likely to degrade over time,
therefore becoming more susceptible to degradation based on patient mishandling. The purpose of
this study was to determine the degree of molecular degradation that occurs in bimatoprost and
latanoprost in a patient-use setting.
Methods: This was an open-label, laboratory evaluation of the relative stability of bimatoprost and
latanoprost. Patients presently using bimatoprost (n = 31) or latanoprost (n = 34) were identified
at 2 clinical sites in Brazil. Patients were instructed to use and store their drops as usual and return
all used medication bottles between day 28 and day 34 after opening.
Results: Bimatoprost demonstrated no degradation, but latanoprost degraded at various levels.
The mean age of bimatoprost was 43.0 ± 3.4 days and the mean age of latanoprost was 43.9 ± 2.8
days (P = .072). The mean percentage of labeled concentration was 103.7% in the bimatoprost
bottles and 88.1% in the latanoprost bottles (P < 001).
Conclusion: This study showed that bimatoprost maintained ≥100% concentration throughout
the study period while latanoprost did not.
Background
The stability of ophthalmic preparations in multidose
containers is influenced by the preservative as well as the
stability of the active ingredient [1]. Unstable drugs may
require refrigeration to preserve their active ingredient
level, therefore becoming more susceptible to degradation
based on patient mishandling. Molecular degradation,
particularly among ocular hypotensive medications, can
occur soon after the container is opened resulting in the
loss of intraocular pressure (IOP)-lowering efficacy and
possibly increasing toxicity.
Numerous clinical studies show that the synthetic prosta-
mide analog, bimatoprost, is a highly efficacious IOP low-
ering agent [2-4]. Bimatoprost is a stable molecule that
does not require refrigeration. Studies show that the pros-
taglandin analog pro-drug, latanoprost, also effectively
lowers IOP [5,6]. However, the active molecule used in
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commercially available formulations is unstable and
requires refrigeration prior to use [7,8]. Latanoprost is
sensitive to extremes in light and temperature [8], and
thus may be particularly susceptible to degradation in
suboptimal storage conditions, which may occur in a
home setting or while a patient is traveling.
Whether temperature and humidity conditions found in
actual practice environments, which vary across geo-
graphic locations and seasons, induce the degree of drug
degradation found under laboratory conditions is not
known. The purpose of this study was to determine
whether storage and use practices of bimatoprost and
latanoprost IOP-lowering medications affect the degrada-
tion rate of the active molecules of these drugs. Sao Paolo,
Brazil, where the medications were used, is located in an
equatorial climate zone characterized by a hot, dry winter
season [9]. Similar to the hot summer in many parts of the
United States and Mediterranean European regions, most
homes are not air conditioned when no one is home dur-
ing the day.
Methods
This was an open-label, laboratory evaluation of the rela-
tive stability of bimatoprost and latanoprost. Patients
presently using bimatoprost (n = 31) or latanoprost (n =
34) were identified at two clinical sites in Sao Paulo, Bra-
zil. After granting informed consent, all patients were
instructed to store and use their eye drops at room temper-
ature and to return all used medication bottles between
day 28 and day 34 after opening. The bottles were col-
lected between May and July 2002.
Quantitative Methods
Once patients returned the used bottles, they were col-
lected and stored at room temperature for subsequent
shipment to a central independent laboratory (Cardinal
Health, San Diego, CA). During shipping (next-day air),
the bottles were stored in insulative packaging with ice
packs. The bottles arrived at the testing facility between
day 35 and day 42. Shipment and arrival of bottles was
scheduled so that all bottles were tested on approximately
day 42 after opening.
All methods were validated by the testing facility, and
analyses were carried out in accordance with good labora-
tory practices. High performance liquid chromatography
(HPLC) was used to separate the molecules of interest
from degradation byproducts and synthetic impurities,
and for quantitation. The method for bimatoprost (AGN
192024) used a Waters Symmetry® C18 reverse-phase col-
umn, UV detection at 210 nm, and a mobile phase of 72/
18/10 (water/acetonitrile/methanol, v/v/v) containing
0.03% (w/v) trifluoroacetic acid. Recovery studies were
conducted for commercially available bimatoprost 0.03%
preserved ophthalmic solution. Studies performed at
80%, 100%, and 125% of the label claim yielded recover-
ies of 100.5%, 100.6%, and 100.2% for peak areas and
101.5%, 100.6%, and 100.4% using peak heights, respec-
tively. Linearity for bimatoprost was demonstrated from
0.002% to 0.009% (w/v) bimatoprost after dilution
(equivalent to 40% to 150% of the AGN 192024 label
claim after dilution). Correlation coefficients (r) of
0.9999 by peak areas and 0.9992 by peak heights were
obtained and a single point standard was used for calcula-
tions using peak areas and peak heights.
For latanoprost, the method employed a Waters 600S
equipped with a Waters 626 pump, a Waters 486 detector,
and a Waters 717 Plus autosampler or equivalent, UV
detection at 205 nm and mobile phase of 6/1/13 (water/
tetrahydrofuran/methanol, v/v/v) containing 0.05% (w/
v) trifluoroacetic acid. Latanoprost stock solution with an
acceptable concentration between 0.45 and 0.55 μg/mL
was used in recovery studies; representing a range from
90% to 110% of the labelled concentration of samples
after 100-fold dilution. A Free Acid Standard, Latanoprost
Standard, Latanoprost and Free Acid Mixed LOQ Stand-
ard, and Latanoprost and Free Acid Mixed Standard were
run against the diluted samples to determine the latano-
prost concentration. A bracketing standard was injected
after every 6-sample injection. The area of the latanoprost
and free acid peaks within this bracketing standard were
within 5% of the average area for the initial five injections
of the latanoprost and free acid peaks. The relative stand-
ard deviation (RSD) for the 5 injections of the latanoprost
and free acid mixed standard were ≤2% for each peak.
Latanoprost concentration was determined using the fol-
lowing formula:
Latanoprost concentration (μg/mL) = (average area latan-
oprost in sample)*(standard latanoprost concentration,
μg/mL)/(average area latanoprost in standard).
The primary endpoint, percentage of labeled concentra-
tion in the bottles at the time of testing, was calculated as:
(concentration of intact drug in bottle/concentration of
the drug indicated on the label) × 100. Percent concentra-
tions then were recorded for each bottle of bimatoprost
and latanoprost.
Statistical Analysis
Between-group comparisons were made using paired t-
tests. The a priori level of significance for all tests was 0.05.
The percentage of label claim was calculated as concentra-
tion remaining in the bottle/label claim × 100.
Results
The bottles were collected between May and July 2002,
which corresponds to the end of fall and the beginning ofBMC Ophthalmology 2008, 8:11 http://www.biomedcentral.com/1471-2415/8/11
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the dry winter season in Sao Paulo. The average ambient
temperature ranged between 14°C and 24°C.
There was no significant between-group difference in the
mean age of the bottles on the test date. The mean bottle
age was 43.0 ± 3.4 days with bimatoprost and 43.9 ± 2.8
days with latanoprost (P  = .072). Bimatoprost bottles
retained a significantly greater percentage of the labeled
active drug concentration after patients completed their
course of therapy than did the latanoprost bottles. The
mean percentage (± SD) of labeled concentration was
103.7% ± 1.3% in the bimatoprost bottles compared with
88.1% ± 10.8% in the latanoprost bottles (P < .001) (Fig-
ure 1), and all (31/31) of the bimatoprost bottles con-
tained  ≥100% of the labeled concentration, compared
with 8.8% (3/34) of the latanoprost bottles at study end.
The percentage of labeled concentration in the latano-
prost bottles ranged from 52% to 115% (Figure 2).
Regression analysis showed that there was no correlation
between the age of the bottles at the time of testing and
the percentage of labeled concentration (r2 = .009, P =
.459).
Discussion
This study demonstrated that bimatoprost maintained its
labeled concentration of active drug, while the latano-
prost active drug concentration degraded over the course
of normal patient use in Sao Paolo, Brazil.
In the present study, the active drug concentration in all
bimatoprost bottles tested was at least 100% of the
labeled concentration more than 40 days after they were
originally opened. Conversely, with latanoprost, only
8.8% of the bottles tested had at least 100% of the labeled
active drug concentration. This result differs from a
patient-use stability study conducted in Los Angeles, Cal-
ifornia, USA, where little degradation of latanoprost was
found [10]. During the winter months when that study
was carried out Los Angeles was in its wet season, in con-
trast to Sao Paolo's dry winter. Ambient temperatures
were higher in Los Angeles during the study (21°C to
35°C), and patients may have been more likely to use air
conditioning, and thus mitigate the effect of environment
on the drug. Latanoprost has been shown to be sensitive
to light and temperature [8,11], and variability in the
actual conditions in which patients stored their medica-
tion may be a differentiating factor between the patient
populations observed in these studies. A heat sensitive
drug is more likely to degrade under improper storage,
and these results might reflect variable storage practices
from patient to patient and between study populations.
One limitation of the study was that baseline concentra-
tions of the drugs were not measured prior to patient use.
However, regulatory agencies and pharmaceutical manu-
facturing specifications require that actual drug concentra-
tions be within a narrow range approximating the labelled
strength. Approximately 10% more or less than the
labelled concentration generally defines this tolerance,
but it may be tighter depending on the characteristics of
the drug [12]. The labelled concentration has been
approved by regulatory agencies and produces the dose at
which efficacy has been demonstrated. Actual concentra-
Frequency distribution of percentage of labeled concentra- tion Figure 2
Frequency distribution of percentage of labeled con-
centration. All of the bimatoprost bottles maintained at 
least 100% of their labeled concentration, whereas latano-
prost concentrations varied.
Mean percentage of concentration in bottles relative to the  label claim at time of testing Figure 1
Mean percentage of concentration in bottles relative 
to the label claim at time of testing. The mean percent-
age (± SD) of labeled concentration was 103.7% ± 1.3% in 
the bimatoprost bottles compared with 88.1% ± 10.8% in the 
latanoprost bottles (P < .001)BMC Ophthalmology 2008, 8:11 http://www.biomedcentral.com/1471-2415/8/11
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tion relative to the target label concentration, as presented
here, gauges drug strength against approved, expected lev-
els.
Whether the degree of drug degradation that occurs under
normal-use conditions is clinically relevant is unclear.
Clinical trials over 1 to 6 months have shown that bimat-
oprost produces IOP reduction greater than or compara-
ble to latanoprost in various patient populations [3,13-
17], and 2 meta-analyses support these conclusions
[18,19]. Whether variable efficacy due to degradation over
time could contribute to these differences has not been
investigated, but future studies that correlate changes in
concentration or degradation with efficacy measures may
be of value.
Loss of drug activity may reduce IOP-lowering efficacy
and cause wide fluctuations in a patient's IOP, which may
be an independent risk factor for progressive disease
[20,21]. Both bimatoprost and latanoprost reduce IOP
over a range of doses [22-25]. Bimatoprost lowers IOP
across a dose range from 0.001% to 0.1% in primates
[24], and has been shown clinically effective at doses from
0.003% to 0.03% [25], with optimal IOP-lowering at the
label dose of 0.03%. Likewise, latanoprost has been
shown most efficacious at its label concentration of
0.005%, but still reduces IOP at 0.001% [22] and
0.0015% [23] concentrations. Even though lower drug
concentrations may reduce IOP, drugs formulated at a
lower concentration, as in the studies referenced above,
may produce a different clinical response than a degraded
medication. Selecting an IOP-lowering medication that is
less sensitive to variation in environmental conditions
may provide the best assurance of continued IOP control
after the bottle is opened, thus reducing the risk of visual
field loss.
Package inserts indicate that bimatoprost should be
stored between 2°C and 25°C, and no shelf life limitation
is indicated [26]. Latanoprost should be protected from
light and refrigerated until opening, after which it may be
stored at room temperature for 6 weeks [7]. Based on the
number of drops dispensed from a 2.5 mL bottle, a bottle
of bimatoprost may be expected to be in use for a maxi-
mum of 56 days, and latanoprost may last up to 47 days
[27], which exceeds the 6 week recommendation for that
drug. Patients who miss doses or otherwise extend the
time a bottle of latanoprost is in use may exceed its recom-
mended in-use life, increasing the risk of degradation and
possibly reduced efficacy. Physicians should encourage
their patients to observe expiration dates and storage
instructions for all medications.
Conclusion
Patients on ocular hypotensive drugs that consistently
lower IOP are less likely to progress than patients whose
medication levels decrease over time. In this study, latan-
oprost formulations degraded while bimatoprost did not,
suggesting that patients are more likely to receive the pre-
scribed dose of bimatoprost after opening. Patients that
receive the labelled dose, which has been clinically shown
to achieve maximal IOP lowering from that medication,
are more likely to halt glaucomatous progression.
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